Literature DB >> 12454565

Neuroleptic Malignant Syndrome with ziprasidone.

Radhika G Murty, Sandeep G Mistry, Ranjit C Chacko.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454565     DOI: 10.1097/00004714-200212000-00015

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  6 in total

1.  Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.

Authors:  Eric Brantley; Jamieson Cohn; Kavita Babu
Journal:  J Med Toxicol       Date:  2009-06

Review 2.  Antipsychotic-induced hyponatraemia: a systematic review of the published evidence.

Authors:  Didier Meulendijks; Cyndie K Mannesse; Paul A F Jansen; Rob J van Marum; Toine C G Egberts
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

Review 3.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 4.  Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.

Authors:  Martino Belvederi Murri; Argentina Guaglianone; Michele Bugliani; Pietro Calcagno; Matteo Respino; Gianluca Serafini; Marco Innamorati; Maurizio Pompili; Mario Amore
Journal:  Drugs R D       Date:  2015-03

5.  Evidence review and clinical guidance for the use of ziprasidone in Canada.

Authors:  David M Gardner; Andrea L Murphy; Stan Kutcher; Serge Beaulieu; Carlo Carandang; Alain Labelle; Pierre Lalonde; Ashok Malla; Heather Milliken; Claire O'Donovan; Ayal Schaffer; Jorge Soni; Valerie H Taylor; Richard Williams
Journal:  Ann Gen Psychiatry       Date:  2013-01-24       Impact factor: 3.455

6.  Ziprasidone in the treatment of mania in bipolar disorder.

Authors:  Stephen E Nicolson; Charles B Nemeroff
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.